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Dr. Louis Bishop is a distinguished physician and cardiol-
ogist who had the vision to see the importance of the or-
ganization which he did so much to create, the American
College of Cardiology. I am honored to deliver this lecture
in Dr. Bishop's honor. Also, I feel fortunate to have a role
in the meeting at which our distinguished colleague and
friend, Dr. Paul Ebert, is presiding.
In about 1965, the United States Government, through
its National Heart Institute, made the decision to stimulate
through research and development a more effective ap-
proach to the understanding and management of the nation's
number one killer, ischemic heart disease. The detailed in-
formation now available about all aspects of ischemic heart
disease bears testimony to the effectiveness of that decision.
Developments in the treatment of coronary artery disease
by coronary artery bypass grafting probably had their gen-
esis in the impetus given to cardiac surgery by the devel-
opment in the I950s of cardiopulmonary bypass by Gibbon,
Lillehei and others. The rather gloomy outlook for many
patients with ischemic heart disease and the introduction of
coronary arteriography by Sones were also powerful stimuli
to the development of surgical treatment by Favaloro, Effler,
Garrett and others.
As a result of such developments, in the current era a
decision must be made between noninvasive and invasive
therapy for most patients with ischemic heart disease. Under
invasive therapy, we include coronary artery bypass graft-
ing, percutaneous transluminal coronary angioplasty and
intracoronary infusion of thrombolytic agents, and we shall
not debate their relative merits. In considering invasive treat-
ment, however, I shall discuss the type with which there is
the longest experience, coronary artery bypass grafting.
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The Plights
Comparison of surgical versus purely medical treat-
ment. One plight in which invasive treatment finds itself
is that there are no studies in the current era, randomized
or nonrandomized, that allow a comparison of invasive treat-
ment with purely medical, noninvasive treatment uncontam-
inated by crossover to invasive treatment. It is tempting to
compare the results of invasive treatment, such as coronary
artery bypass grafting, with those of medical treatment in
the late 1960s and early 1970s (1-4). But this is not ap-
propriate because medical therapy in the current era is con-
siderably more effective than in the earlier eras (5-7). At-
tempts to solve this plight by actuarial analysis of randomized
trials by treatment received rather than prescribed by ran-
domization also face serious criticism. Censoring of ran-
domly assigned patients is required in such attempts, and
the resultant actuarial estimates are affected in an unknown
way by a method of censoring in which the believed im-
minence of the event under study (death) leads to the cir-
cumstances (coronary artery bypass grafting) that result in
censoring.
In spite of this dilemma, inferences concerning the role
of invasive treatment in the management of patients with
ischemic heart disease must be made. They are made with
the greatest degree of certainty when based on randomized
clinical trials, even though none of these tests the efficacy
of invasive therapy against that of purely and consistently
noninvasive medical treatment without crossover to surgery.
Therefore, the inferences must be carefully drawn to be
certain that they are in the context of the randomized clinical
trials from which they are drawn.
Subsets of ischemic heart disease. However, another
plight is that there are many subsets of ischemic heart disease
that have not been, and may never be, addressed by ran-
domized clinical trials. Yet, the everyday challenges of pa-
tient care cannot be dismissed by the nihilistic answer "we
don't know, " since this is both inconsiderate of the human
lives at stake and irrational in view of other information that
is available. This information comes from in-depth studies,
by appropriate methods of analysis, of properly defined
clinical experiences. Although the inferences from these
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Figure 1. Actuarial survival of patients randomly as-
signed to medical or surgical treatment in the CASS
randomized trial (8). The patients, younger than 66
yearsof age, were either asymptomaticafter a previous
myocardial infarction or had mild stable angina (class
lor II). Seventy-twopercentof the patientshad normal
or near normal left ventricular function at rest; 30%
had a severe proximal lesion in the anterior descending
coronaryartery. (Reproducedfrom CASS Principal In-
vestigators and Their Associates [8] with permission
of the American Heart Association. Inc.)
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studies come from informal comparisons and must, there-
fore, be made with a lesser degree of certainty than those
based on randomized trials, they can be useful in the care
of patients.
The Inferences
It is the purpose of this lecture to develop a series of
inferences concerning the management of patients with isch-
emic heart disease, based on randomized clinical trials and
on an as yet incomplete analysis of 3,872 patients treated
by coronary artery bypass graft surgery at the University of
Alabama in Birmingham between January 1977 and January
1981, in 99.6% of whom there is complete follow-up
information.
In general, patients with stable and mild or moderate
angina, or who are asymptomatic after an acute myo-
cardial infarction, and with good left ventricular func-
tion may be assigned to initial noninvasive treatment and
close continued observation. Invasive therapy is advised
if symptoms worsen. CASS trial. As a general statement,
this is the most important inference to be drawn from the
Coronary Artery Surgery Study (CASS) randomized trial
(8). The 5 year survival rate of 90% for the patients assigned
to initial medical treatment is nearly as good as the 92%
survival rate for patients initially assigned to surgery (Fig.
1). The p value of 0.34 indicates that this small difference
is very likely due to chance. This finding is amplified by
the report that the 5 year survival rate, free of nonfatal
myocardial infarction, was also similar in the two treatment
groups (9). The particular characteristics of the total group
of patients (Fig. I) and the design of the trial itself have
been carefully considered in drawing this inference.
The design of the study allowed crossover to surgery of
patients assigned to medical treatment when. in the judg-
ment of the cardiologist, this best served the patient's well-
being. Most of the crossovers were made because of wors-
ening angina. Among patients with single vessel disease.
10% of patients crossed over to surgery within 5 years, and
among those with triple vessel disease, 38% switched to
surgical treatment (Fig. 2). The magnitude of the incidence
of crossover necessitates the inclusion in the inference of
the phrase "with close continued observation and invasive
therapy if symptoms worsen."
Figure 2. Actuarial depiction of crossovers (shown
as the inverse "% without surgery") from assigned
treatment in the CASS randomized trial (8). Cross-
overs to surgery by patients initially assignedto med-
ical treatment (MED ASSIGN) are indicated by the
solid lines, stratified by number of vessels with 70%
or greater stenoses (I, 2 and 3 YES). (Reproduced
from CASS Principal Investigators and Their Asso-
ciates [8] with permission of the American Heart
Association, Inc.)
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This finding cannot be interpreted as showing that sur-
gical treatment as compared with solely medical treatment
is ineffective in prolonging life since the design of the trial
precluded gathering information relevant to that hypothesis.
Also, it may be that the survival rate would be lower in the
group assigned to initial medical therapy if the crossovers
had not been allowed.
European randomized trial. As a general statement, this
inference is tenable also in the context of the European
randomized trial of surgical treatment (I Q), which included
only patients with good left ventricular function (ejection
fraction >0.50) and mild or moderate angina and which
also allowed crossover. In that study, when double or triple
vessel disease did not include a severe proximal left anterior
descending lesion, initial assignment to surgical treatment
did not improve survival.
As exceptions to the first inference, patients with left
main coronary artery disease and those with important
proximal left anterior descending coronary artery dis-
ease may be assigned to initial invasive therapy even
though left ventricular function is good and the other
stipulations of the first inference are met. Left main dis-
ease. This inference, as regards patients with left main
coronary artery disease. is supported by the United States
Veterans Administration randomized trail of coronary artery
surgery (II). With a lesser degree of certainty (p= 0.12),
perhaps because of the small number of patients. this in-
ference is also supported by the European trial (9). Patients
with severe left main disease were not included in the CASS
randomized trial.
Proximal left anterior descending artery disease. The
inference with regard to patients with important( 2:50%) ste-
Table 1. Patients Undergoing Primary Coronary Bypass Grafting* (University of Alabama in
Birmingham; 1977 to 19~1)
Hospital Deaths
Category of CABG n No. % CL
Isolated 3,610 26 0.72% 0.58 to 0.90%
With LV resection 177 8 4.5% 2.9 to 6.8%
With valve surgery for 51 8 16% 10 to 23%
ischemic mitral
incompetence
With closure of 16 3 19% 8 to 34%
postinfarction VSD
With operation for 18 6% Ito 18%
ventricular tachycardia
Total 3,872 46 1./9% 1.0 I to 1.40%
p (X") < O.DOOI
*Excluded are patients undergoing concomitant or prior valve operations for nonischemic valvular disease;
3,850 (99.6%) of the patients are traced. CABG = coronary artery bypass grafting; CL = 70% confidence
limits; LV = left ventricular; VSD = ventricular septal defect.
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Months after Cardiopulmonary Bypass
nosis in the proximal left anterior descending coronary artery
is strongly supported (p =0.003) by the European random-
ized trial (10). The finding was not supported by the CASS
randomized study (8). Thus. this inference is made with a
lesser degree of certainty than the previous one. If it be-
comes important to increase the degree of certainty, a ran-
domized trial that focuses on this matter could be consid-
ered. Also, if it becomes important to know which type of
invasive therapy is most appropriate in this setting, partic-
ularly in the case of double vessel disease with severe prox-
imal left anterior descending coronary artery disease, a ran-
domized trial focused on this issue could be considered.
Patients with impaired left ventricular function and
triple vessel disease, even though asymptomatic after an
0.025
acute myocardial infarction or with only mild chronic
stable angina may have improved survival rates when
initially assigned to invasive therapy. No randomized trial
has been directed specifically at the patients referred to in
this inference, and no cases of this type are included in the
European trial (10). Only 27% of the patients in the CASS
randomized trial had less than good left ventricular function,
but the original randomization process was stratified by left
ventricular function and. thus. some information is avail-
able. Patients with chronic, stable, mild or moderate angiria
and left ventricular ejection fraction less than 0.50 had a
higher 5 year survival rate (96%) when assigned to surgical
treatment than that (85%) of patients assigned initially to
medical treatment and with the opportunity for crossover to
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Figure 5. Hazard function (instantaneousrisk
of death per month, shown along the vertical
axis) after primary isolated and combined
coronary artery bypass grafting (University
of Alabama in Birmingham; 1977 to 1981;
n = 3,872, 460 deaths; see Table 1 for pa-
tient categories). The dashed lines around
the solid line in this and subsequent figures
enclose the 70% confidence limits. Other as-
pects of format as in Figure 4.
Months after Cardiopulmonary Bypass
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Table 2. Coronary Artery Bypass Grafting*
Hazard Phase
Early Intermediate
Incremental Risk Factor Coefficient ± SD p Value Coefficient ± SD p Value
CASS LV score (5 to 30)t 0.11 ± 0.032 0.001 0.11 ± 0.026 <0.0001
Left ventricular end-diastolic 0.066 ± 0.0113 <0.0001
pressure (rnm Hg)
Age (yr) at operation 0.08 ± 0.023 0.0003
Aortic cross-clamp time (min) 0.018 ± 0.0053 0.0008
Left ventricular resection 1.5 ± 0.38 0.0001
Valve surgery for ischemic mitral 1.6 ± 0.51 0.0009
incompetence
Operation for intractable 1.5 ± 0.59 0.01
ventricular tachycardia
Earlier date of operation (rno) -0.020 ± 0.0113 0.08
Intercept -9.9 -8.6
Late
Coefficient ± SD
0.072 ± 0.0164
1.1 ± 0.39
1.8 ± 0.86
-7.9
p Value
<0.0001
0.006
0.04
*Risk factors for premature death after primary, isolated or combined coronary artery bypass grafting (University of Alabama in Birmingham; 1977
to 1981; n = 3,872,460 deaths; see Table I for patient categories). Twenty-nine preoperative and intraoperative variables, including those describing
the extensiveness of the coronary artery disease and the presence or absence of left main disease, were entered. Only those shown in the table had a p
value <0.20 and were retained. tLeft ventricular wall motion score. CASS = Coronary Artery Surgery Study; LV = left ventricular; SD = standard
deviation.
surgery (Fig.3) (8). The p value of 0.057 deserves something
more than being dismissed as indicating "statistical insig-
nificance." This p value indicates that probably this dif-
ference is not due to chance. and that probably it would
appear in a similar group managed in an identical fashion.
Thus inferences, although not certainty, can be drawn from
this subset of patients, rather than simply rejecting the hy-
pothesis that initial surgical therapy improves the survival
rate. This was implied clearly by Fisher (12), who stated
that "no scientific worker has a fixed level of significance
at which from year to year, and in all circumstances he
rejects hypotheses; he rather gives his mind to each partic-
ular case in the light of his evidence and his ideas."
This inference, made with slightly less certainty than the
previous ones because of the p value of 0.057 , is compatible
with the findings of the Veterans Administration randomized
study (I I) as well as the results of nonrandomized studies
(13,14).
Patients with severe angina (class III or IV) may have
improved survival when initially assigned to surgical
therapy. Intuition and clinical experience suggest this in-
ference, even though the place of invasive therapy in this
group of patients is often dismissed as being "for relief of
symptoms only." In fact, there is no proper study to test
the null hypothesis that initial assignment to invasive therapy
does not result in a better survival rate than initial assignment
Table 3. Hospital Mortality After Primary Isolated Coronary Artery Bypass Grafting (University
of Alabama in Birmingham; 1977 to 1981)
Hospital Deaths
Vessel Disease n No. % CL
Left main = no 3,031 21 0.69 0.54 to 0.89%
With I vessel disease 334 2 0.6 0.2 to 1.4%
With 2 vessel disease 1,099 8 0.7 0.5 to 1.1%
With 3 vessel disease 1,559 II 0.7 0.5 to 1.0%
Vessel disease unknown 39 0 0 0 to 5%
Left main = yes 548 5 0.9 0.5 to 1.6%
With no other disease II 0 0 a to 16%
With I vessel disease 43 0 0 0 to 4%
With 2 vessel disease 167 2 1.2 0.4 to 2.8%
With 3 vessel disease 317 3 0.9 0.4 to 1.9%
Vessel disease unknown 10 0 0 0 to 17%
Left main = unknown 31 0 0 0 to 6%
Total 3,610 26 0.72 0.58 to 0.90%
P(X2) = 0.99
CL = 70% confidence limits.
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Figure 6. Effect of left ventricular (LV) function (expressed as
CASS left ventricular segmental wall motion score and. in paren-
theses. left ventricular ejection fraction [EF]) on survival after
coronary artery bypass grafting (University of Alabama in Bir-
mingham; 1977 to 1981). A. Hazard function (instantaneous risk.
or incidence. of death per month). B. Parametric estimates of
survival. These nomograms are solutions of the multivariate equa-
tion in Table 2. The values for ejection fraction are obtained from
a regression analysis of the relation of ejection fraction to CASS
left ventricular wall motion score in the 3.872 patients (r = 0.73l.
Left ventricular resection. surgery for ischemic mitral incompet-
ence and surgery for intractable ventricular tachycardia were set
at No. age was set at 56 years (median value for the n = 3.610)
and aortic cross-clamp time at 50 minutes (median value). Left
ventricular end-diastolic pressure was set at the median value for
each of the four specific CASS scores (10 mm Hg. 13 mm Hg,
17 mm Hg and 22 mm Hg for scores of 7. 15. 20 and 25.
respectively).
to a considerable period of medical treatment. If it is con-
sidered important to resolve this issue with greater certainty.
a randomized trial specifically directed to this issue could
be undertaken.
Coronary artery bypass grafting neutralizes the in-
cremental risk for premature death from multivessel
disease including left main disease. This inference is made
from an in-depth analysis of all patients undergoing bypass
surgery for ischemic heart disease at the University of Al-
abama in Birmingham between January I. 1977 and January
I. 1981 (Table I). The 5 year actuarial survival rate from
time 0 (defined as the moment in the operating room when
cardiopulmonary bypass was discontinued) is 86.5% (Fig.
4). Hazard function analysis (Blackstone et al. Unpublished
observations) for the instantaneous incidence (risk) of death
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Figure 7. Survival in patients with coronary artery
disease and ejection fraction (ejecfr) less than 0.25.
with initial treatment by coronary artery bypass graft-
ingor by initial medical treatment. (Reproduced from
Alderman et al. [16] with permission.)
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over time (Fig. 5) shows an early phase of rapidly declining
hazard (instantaneous risk) ending at about 6 months , an
intermediate phase of low constant hazard and a late phase
of slowly increasing hazard beginning about 3.5 years after
operation. Multivariate analysis (Blackstone et al. Unpub-
lished observations) (Table 2) indicates that the extensive-
ness of the coronary artery disease, including multivessel
and left main disease, is not a risk factor for premature death
in any phase . As a check, the effect of extensiveness of the
coronary artery disease (Table 3) and the number of distal
anastomoses (p =0.7) on hospital mortality was examined
and found to be nonexistent. Also of interest is the absence
of femaleness as a risk factor , which is perhaps related to
the near routine use of sequential grafting for vessels as
small as I mm in diameter.
Coronary artery bypass grafting does not neutralize
the incremental risk for premature death from left ven-
tricular dysfunction, but improves the prognosis in pa-
tients with moderate dysfunction and possibly in those
with severe dysfunction. Left ventricular dysfunction, ex-
pressed in the CASS as left ventricular segmental wall mo-
tion score or by ejection fraction , is associated in our ex-
perience with a longer and higher initial phase of hazard
function and a higher intermediate phase of constant risk.
but not with an accelerated or increased late hazard phase
(Fig. 6A). This resulted in a probability of 5 year survival
for CASS scores of? (ejection fraction 2:0 .50), 15 (ejection
fraction = 0.40), 20 (ejection fraction = 0.30) and 25
(ejection fraction = 0.15) of 93, 87, 78 and 59%, respec-
tively (Fig. 68). In the case of patients with CASS wall
motion scores between 7 (ejection fraction = 0.50) and 17
(ejection fraction = 0.30) , the survival rate is probably
better in those assigned initially to surgery than in those
assigned initially to medical treatment (Fig. 3). An informal
comparison of our results with those of initial assignment
to medical treatment in the CASS registry (15,16) supports
this conclusion (Fig. 7). Whether this is true of patients
whose left ventricular function is severely depressed (ejec-
tion fraction < 0.30) is not known, but an informal com-
parison with data from the CASS registry (15) suggests that
it is, at least in patients with triple vessel disease. If it is
deemed important to make these comparisons in a formal
way, a randomized trial of this issue could be undertaken.
Older age and longer aortic cross-clamp time are in-
cremental risk factors, but their effect is weak. This is
evident from inspection of nomograms depicting this (not
presented).
Left ventricular resection (for aneurysm) at the time
of coronary bypass surgery is associated with a lower
survival rate than otherwise would be the case. The haz-
ard function for patients with left ventricular resection is
increased in the early and late phases compared with that
of similar patients who did not undergo resection for left
ventricular aneurysm (Fig. 8A). This is reflected in the
parametrically determined 5 year survival rate of 73% as
compared with that of 83% for comparable patients without
left ventricular resection (Fig. 88) . This does not deny that
the survival rate after left ventricular resection is better than
it would be in such patients without resection . This inference
is compatible with the study of Froehlich et al. (17). which
showed that the resection of a left ventricular aneurysm
improves ejection fraction only when the aneurysm is large.
The reasons that left ventricular resection is an incre-
mental risk factor for premature late death are not apparent ,
but may be related to the effect of the resection or recon-
struction on left ventricular structure and function. Until
improved methods are developed, resection may be advis-
able only for large aneurysms.
Surgical correction of important ischemic mitral in-
competence at the time of coronary bypass surgery is
associated with a lower survival rate. The incremental
risk of surgery for ischemic mitral incompetence along with
JACC Vol. 5, No.1
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Figure 8. Effect of left ventricular
(LV) resection for aneurysm, along
withcoronary artery bypass grafting,
on survival (University of Alabama
in Birmingham; 1977 to 1981 ). A,
Hazard function (instantaneous risk,
or incidence, of death per month).
B, Parametric estimates of survival.
These nomograms are solutions of
the multivariateequation in Table 2.
Operation for intractable ventricular
tachycardia and operation for isch-
emic mitral incompetence were en-
tered at No. The median values of
the other variables in patients
undergoing left ventricular resection
were entered into the equations for
both left ventricular resection yes and
no. These were: CASS left ventric-
ular segmental wall motion score
= 15, left ventricular end-diastolic
pressure = 20 mm Hg, aortic cross-
clamp time= 50 minutes.
YES
60
NO
l V RESECTION
YES
60
54
54
48
4842
42
36
36
30
30
24
24
18
18
12
12
Months after Cardiopulmonary Bypass
6
6
Months after Cardiopulmonary Bypass
-- - -- --- --
- -- -- ---
-- -- -- ---- -- -- ----- --
.
' .
.. .
...\ ,
.... \ ,
..::-::... :~__r::._~_._~_ ._-~:-~ .:~.~ _~~::....:~: .It:::~:~: ::: _-~.:: _.'_. -_.' --
o.000 L.....~....L~.........J~~w......~_...J.~~--'--'--~........L~~.u...~_'_'_~~..........~.w
o
A
0 .025
I 0. 0 20fIl
.s::.
-c:0
~
.s::. 0 .015
-as
Ql
C
-0 0 . 010
Ql
U
c:
Ql
"C
o 0.005
.E
1.00
.90
.80
'lU
>
.70.;
...
::l
(J)
.60
-0
.50
>-
::
:c .40
as
~
.300
...
ll.
. 20
.10
0
0
B
coronary artery bypass grafting is only in the early phase
(Table 2), but result s in a probability of survival at 5 years
of 66%, in contrast to one of79% for similar patients (CASS
left ventricular wall motion score = 13, left ventricular end-
diastolic pressure = 20 mm Hg. age = 62 years, aorti c cross-
clamp time = 90 minutes , left ventricular resection in 20%)
undergoin g bypass surgery without mitral valve surgery .
Presumably the 5 year survival rate is better than that of
similar patients with ischemic mitral inco mpetence recei ving
only bypa ss grafting, but further study is required of this
point as well as of the magn itude and type of incompeten ce
that requ ire valve repair or replacement. The increased risk
during the early phase is probably related to the abrupt
increase in left ventricular afterload resulting from the sud-
den ablation of the mitral incompetence (18). The lack of
any increased risk in the intermediate and late phases sug-
ges ts that spec ial situations (papillary muscle scarring, chor-
dal rupture , secondary valvular changes) account for the
incompeten ce rather than generalized left ventricular dys-
function , and that once survival is assured through the early
phase , the later result s are satisfac tory .
Operations for intractable ventricular tachycardia
often, in the era studied, failed to control the arrhythmia
or worsened left ventricular dysfunction, or both. Thi s
inference is deri ved from the increase d instantaneous risk
for premature death during the intermediate and late phases
in this situation, result ing in a probabilit y of 5 year surviva l
of 27% in contrast to that of 73% for similar patients without
intractable ventricular tachycardia (Fig . 9). Thi s situation
may be improved in the current era by better diagnostic
methods and surgical techniques for the control of intract-
able ventricular arrhythmias .
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Figure 9. Effect of operations di-
rected at life-threatening ventricular
(V) tachycardia. along with coronary
artery bypass grafting, on survival
(University of Alabama in Birming-
ham; 1977to 1981). A, Hazard func-
tion (instantaneous risk. or inci-
dence, of death per month). B,
Parametric estimates of survival.
These nomograms are solutions of
the multivariateequation in Table 2.
The variables for the equations for
both operation for ventricular tachy-
cardia yes and no were set at the
median value for patients with op-
eration directed at intractable ven-
tricular tachycardia. These were:
CASS left ventricular segmental wall
motion score = 17, left ventricular
end-diastolic pressure = 20 mm Hg,
age = 56 years, aortic cross-clamp
time = 64 minutes, left ventricular
resection in 70% of the group and
mitral valve surgery in 0%.
Coronary bypass surgery should be deferred as long
as is reasonably safe because of the increase in hazard
function which begins about 3.5 years after opera-
tion. This gradually increasing hazard function of the late
phase is apparent in Figure 5. In general, bypass surgery
or some other form of invasive therapy is probably indicated
only when the probability of early death with continuing
medical treatment exceeds 10%.
Comment
By a combination of the information from randomized
clinical trials and from in-depth studies of other clinical
experiences, a series of useful inferences can be drawn
concerning invasive therapy for ischemic heart disease, al-
beit with variable degrees of certainty. The process of de-
riving these inferences indicates how much new information
is needed to increase knowledge and still further improve
results.
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